Amgen Inc. v. F. Hoffmann-LaRoche LTD et al
Filing
1207
DECLARATION re #1206 MOTION To Preclude the Testimony of Dr. Thomas Kadesch Based on Roche's Representation That It Would Not Call Dr. Kadesch At Trial, Or, In The Alternative, To Limit His Testimony Regarding Obviousness-Type Double Patenting To the Two Sentences On This Issue Contained in His Expert Report, Declaration Of Aaron R. Hand by Amgen Inc.. (Attachments: #1 Exhibit 1#2 Exhibit 2#3 Exhibit 3)(Gottfried, Michael)
<![CDATA[
Amgen Inc. v. F. Hoffmann-LaRoche LTD et al
Doc. 1207 Att. 1
Case 1:05-cv-12237-WGY
Document 1207-2
Filed 09/30/2007
Page 1 of 2
Exhibit 1
Dockets.Justia.com
Case 1:05-cv-12237-WGY
Document 1207-2
Filed 09/30/2007
Page 2 of 2
KAYE SCHOLER LLP
Patricia A. Carson 212 836-7466 Fax 212 836-8689 pcarson@kayescholer.com 425 Park Avenue New York, New York 10022-3598 212 836-8000 Fax 212 836-8689 www.kayescholer.com
September 29, 2007 VIA EMAIL Renee DuBord Brown, Esq. Day Casebeer Madrid & Batchelder LLP 20300 Stevens Creek Blvd, Suite 400 Cupertino, California 95014 Re: Dear Renee: Defendants give notice that Dr. Thomas Kadesch is expected to testify on October 1, 2007 during the afternoon hearing on obviousness type double patenting. Very truly yours, /s/ Patricia A. Carson Patricia A. Carson PAC/jlm cc: Leora Ben-Ami Thomas Fleming Julia Huston Aaron Hand Alison Maddeford Jeremy Jordan Rachelle Platt Michael Gottfried Amgen, Inc. v. F. Hoffman-La Roche Ltd, Roche Diagnostics GmbH, and Hoffmann-LaRoche Inc., Civ. No. 05-CV-12237WGY, D. Mass
31545602.DOC
New York
Chicago
Los Angeles
Washington, D.C.
West Palm Beach
Frankfurt
London
Shanghai
]]>
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?
